

## Assessment of Susceptibility to Five Common Antibiotics and Their Resistance Pattern in Clinical Enterococcus Isolates

Sara Masoumi Zavaryani<sup>1</sup>, Reza Mirnejad<sup>\*2</sup>, Vahhab Piranfar<sup>\*3</sup>,  
Mehrdad Moosazadeh Moghaddam<sup>4</sup>, Nikta Sajjadi<sup>5</sup>, Somayyeh Saeedi<sup>6</sup>

1. Department of Microbiology, Islamic Azad University of Varamin-Pishva Branch, Tehran, Iran
2. Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
3. Research and Development Department, Farname Inc., Thornhill, Canada
4. Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
5. CNC, Center of Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
6. Department of Microbiology, Faculty of Advanced Sciences and Technology, Pharmaceutical Sciences Branch Islamic Azad University, Tehran, Iran (IAUPS)

### KEYWORDS

*Enterococcus faecalis*,  
*Enterococcus faecium*,  
Multiple drug resistance,  
Correlation

Scan to discover online



Main Subjects:  
Microbiology

Received 08 Sep 2019;

Accepted 27 Jan 2020;

Published Online 19 Feb 2020;

 [ijp.2020.114009.2236](https://doi.org/10.2345/2345-3656.2020.114009.2236)

PMCID:

PMID:

### ABSTRACT

**Background & Objective:** Enterococcus Species are the common cause of nosocomial infections, which are highly resistant to different antibiotics. Therefore, determination of their antibiotic susceptibility patterns and simultaneous resistance to antibiotics is important for better treatment strategies.

**Methods:** 400 clinical *Enterococcus* isolates were collected from different hospitals in Tehran, Iran. Standard phenotypic-biochemical tests and PCR were used to identify the *Enterococcus* species. The antimicrobial susceptibility patterns and simultaneous resistance to selected antibiotics were determined by disk diffusion method according to the CLSI guidelines. All data analysis was performed using Python packages Scipy and Stats models.

**Results:** According to the biochemical and PCR analyses, among 400 *Enterococcus* species, 72% of samples were *Enterococcus faecalis*, 10.75% *Enterococcus faecium*, and 17.25% other *Enterococcus* species. The results determined antimicrobial resistances of these strains against gentamicin, vancomycin, fosfomycin trometamol, teicoplanin, and quinupristin/dalfopristin. Results confirmed a significant correlation between resistance to vancomycin and resistance to teicoplanin. This correlation remains significant when including only *E. faecium* or *E. faecalis* species. We also found a negative correlation between resistance to teicoplanin and quinupristin/dalfopristin. Additionally, Quinupristin/dalfopristin was the least effective antibiotic while vancomycin and teicoplanin were the most effective ones.

**Conclusion:** Based on the results and association between simultaneous resistance to some antibiotics such as vancomycin and teicoplanin, in the case of antibiotic resistance, the choice of a second antibiotic can be very important which can lead to good or bad effects.

**Corresponding Information:** Reza Mirnejad, Associate Professor of Bacteriology, Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. Email: [rmirnejad@bmsu.ac.ir](mailto:rmirnejad@bmsu.ac.ir)  
Vahhab Piranfar, Research and Development Department, Farname Inc., Thornhill, Canada  
Email: [yahab.p@gmail.com](mailto:yahab.p@gmail.com)

Copyright © 2020. This is an open-access article distributed under the terms of the Creative Commons Attribution- 4.0 International License which permits Share, copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, even commercially.

### Introduction

*Enterococcus* species are a major part of the gastrointestinal tract which is responsible for 10% of hospital-acquired infections (1-3). The most common human infectious strains of *Enterococcus* are *E. faecalis* (85–90%) and *E. faecium* (10-15%) leading to urinary tract infections, endocarditis, bacteremia, wound infection, abdominal infections, pelvic infections, and meningitis (4). On the other hand, about 30% of all nosocomial bloodstream infections are

associated with *Enterococcus* species and *Staphylococcus aureus*, resulting in significant morbidity and mortality (5-8). Based on the United States Nosocomial Infections Surveillance System's data, *Enterococci* are considered as one of the nosocomial pathogens (9). These bacteria are ranked fourth in nosocomial infectious agents, third in bacterial infections, and second in pathogens causing urinary tract infections, which has prompted some to

consider a worldwide emergence of antibiotic-resistance in these species (10). Since these bacteria can live in a wide range of environments, their identification is essential for controlling and prevention of infections (11-13). On the other hand, *Enterococci* are tolerant to the bactericidal activity of cell-wall active agents, such as  $\beta$ -lactam antibiotics and vancomycin. *Enterococcal* tolerance to these antibiotics can be affected by combining cell-wall active agents with an aminoglycoside based on synergistic bactericidal activity. Studies have shown that a higher concentration of aminoglycoside enters cells that are also treated with agents that inhibit cell wall synthesis, which suggests that the cell wall active agents promote uptake of the aminoglycoside (5, 14). Accordingly, to treat infections caused by *Enterococci*, combination therapy with a cell wall-active agent and a synergistic aminoglycoside should be considered. Nevertheless, in recent years, resistance to aminoglycosides and decreased susceptibility to  $\beta$ -lactam antibiotics and vancomycin, makes their synergistic function less efficient (15-19). Therefore, the widespread resistance of *enterococci* has a significant impact on the selection and use of synergistic antibiotics for the treatment of *enterococcal* infections. Given the importance of this issue, in this study, we collected clinical samples to contain different *Enterococcus* species and then analyzed resistance pattern of each sample against five common antibiotics. In the following, the correlation between resistance to antibiotics and simultaneous resistance to selected antibiotics was investigated. The findings can help better understand the trends of antibiotic resistance of *Enterococcus* species, and guide strategies for the use of antibiotics.

## Materials and Methods

### Sample Collection

We conducted a cross-sectional study on 400 clinically *Enterococcus* spp. Samples (urine, wound, blood, ascites, etc.) were randomly collected from Baqiyatallah and Milad hospitals (Tehran, Iran), from

January to December 2017. The samples were collected from patients of all age groups and both genders, without any restrictions on the cause of hospitalization.

### Identification of *Enterococcus* Species

#### -Phenotypic-Biochemical Tests

To identify *Enterococcus* species by biochemical test, 24-hour pure blood agar medium was produced. Next, the following tests were performed on each sample: gram staining, catalase test, bile salt hydrolysis (40% bile salts), growth on Brain Heart Infusion (BHI) medium containing 6.5% salt (NaCl), and sugar fermentation tests of arabinose, mannitol, sorbitol, sorbose and lactose (20).

#### -PCR Analysis

For identification by PCR, the DNA of *Enterococcus* species was extracted using the boiling method (21). Commercially synthesized primers specific to genes (D-AlaD-Ala) of *E. faecalis* and *E. faecium* were obtained from Pishgam Biotech Company (Tehran, Iran) (21-23). The oligonucleotide sequences are shown in [Table 1](#). PCR reaction was performed in final volume of 25  $\mu$ L containing 1  $\mu$ L of template DNA (50 ng/ $\mu$ L), 1 $\mu$ L of each primer (10 pmol), 12  $\mu$ L of Taq 2X Mastermix (Ampliqon III company, Denmark) including 20 mM dNTP, 1.5 mM MgCl<sub>2</sub> and 1X PCR buffer) and 11  $\mu$ L of double-distilled water. PCR performed for amplification of the aforementioned genes in Eppendorf thermal cycler (Eppendorf AG, Hamburg, Germany,) using the following cycling parameters: a denaturation at 94°C for 10 min, followed by 35 cycles each of 94°C denaturation for 1 min, annealing at 55°C for 1 min and initial elongation at 72°C for 2 min and final extension at 72°C for 5 min. PCR products (941bp for *E. faecalis* and 550 bp for *E. faecium*) were analyzed by electrophoresis using 1.5% agarose gel and visualized and analyzed by Safe Satin staining with the help of Gel Documentation system (Cambridge, England, Uvitec) and a 100 bp DNA Ladder (Green BioResearch LLC, USA). The amplified PCR products were confirmed by sending the samples for sequencing (Bioneer, Korea).

**Table 1.** The sequence of the primers used in PCR amplification of (D-Ala D-Ala) *E. faecalis* and (D-Ala D-Ala) *E. faecium* genes

| Target genes                        | Primer sequence (5' → 3')                                  | Amplicon size | Reference |
|-------------------------------------|--|---------------|-----------|
| (D-Ala D-Ala)<br><i>E. faecalis</i> | Forward: ATCAAGTACAGTTAGTCT<br>Reverse: ACGATTCAAAGCTAACTG | 941 bp        | (56)      |
| (D-Ala D-Ala)<br><i>E. faecium</i>  | Forward: TAGAGACATTGAATATGCC<br>Reverse: CTAACATCGTGTAAGCT | 550 bp        | (56)      |

### Antimicrobial Susceptibility Tests

Susceptibility tests for antibiotics (Mast Group, Merseyside, UK) including gentamicin (10  $\mu$ g), vancomycin (30  $\mu$ g), teicoplanin (30  $\mu$ g), fosfomycin trometamol (50  $\mu$ g) and quinupristin/dalfopristin (15  $\mu$ g) were performed on Mueller-Hinton agar (Merck Co., Germany) plates using disc diffusion method according to the guidelines of Clinical and Laboratory Standards Institute (CLSI) (24). *E. faecalis* ATCC 2921 (25) was used as a reference strain for antibiotic susceptibility

tests. Also, according to the CLSI recommendation for *Enterococcus* species, minimum inhibitory concentration (MICs) of vancomycin was performed for resistant isolates by microdilution method in BHI broth medium and different concentrations (4 – 1024  $\mu$ g/mL) of antibiotic (24, 26).

### Statistical Analysis

We performed all data analysis using Python packages Scipy (version 0.19.1) and Stats models (version 0.8.0).

## Results

### Sample Distribution

Of 400 *Enterococcus* isolated clinical samples, 83.75% (335 samples), 6% (24 samples), and 3.25% (13 samples) were isolated from urine, wound, and blood, respectively and 7% (28 samples) were isolated from other locations (vagina, sputum, ascites, and Bronchoalveolar lavage). All age groups entered the study (maximum age of 87 years). There were 185 (46.25%) males and 215 (53.75%) females.

### Identification of *Enterococcus* Species

PCR results showed that 288 (72%) isolates were of *E. faecalis*, 43 (10.75%) *E. faecium* and the remaining 69 (17.25%) other *Enterococcus* species. PCR was mainly used to identify *E. faecalis* and *E. faecium* (Figure 1). Using a BHI+ NaCl 6.5% test (27), we confirmed that these 69 strains were from other *Enterococcus* species.




**Fig. 1.** An example of gel electrophoresis of PCR products used to identify *Enterococcus* species. Lane A. is marker DNA (100 bp), Lane B. is non-template DNA sample, Lane C. is an amplified (D-Ala D-Ala) *E. faecium* (550 bp) gene in clinical samples examined, Lane D. is an

amplified (D-Ala D-Ala) *E. faecalis* (941 bp) product of clinical samples examined.

### Antibiotics Resistance Pattern & Association Between Simultaneous Resistance to Selected Antibiotics

Kirby-Bauer antibiotic tests (28) were performed to identify *Enterococcus* isolates resistant to Gentamicin, vancomycin, teicoplanin, fosfomycin trometamol, and quinupristin/dalfopristin. Antibiotic resistance patterns in bacteria samples are shown in Figure 2. Isolated samples were categorized based on their origin, i.e., urine, blood, and wound samples, or samples from sites that we labeled as “others”, due to their low frequencies. The “other” sites from which samples were taken include the vagina, sputum, ascites, and bronchoalveolar lavage. Samples categorized as sensitive, semi-sensitive or resistant to each antibiotic using disk diffusion method, according to the guidelines of CLSI (24).

Our results confirmed that resistance to teicoplanin is correlated with resistance to quinupristin/dalfopristin and vancomycin. Accordingly, we found a strong correlation between the resistance of samples to vancomycin and teicoplanin (Pearson's  $r=0.36$ ,  $P=8.44 \times 10^{-14}$ ). The two antibiotics also showed significant correlations when we included only *E. faecalis* (Pearson's  $r=0.36$ ,  $P=3.71 \times 10^{-10}$ ) or *E. faecium* (Pearson's  $r=0.63$ ,  $P=5.21 \times 10^{-6}$ ) species. Indeed, the correlation was considerably stronger when considering only *E. faecium*. Furthermore, there was a nearly significant and negative correlation between resistance to quinupristin/dalfopristin and teicoplanin (Pearson's  $r=-0.10$ ,  $P=0.05$ ). This correlation was very significant, if we consider non-sensitivity of samples to the antibiotics, that is, samples that are completely or partially resistant to the two antibiotics (Pearson's  $r=-0.15$ ,  $P=2.44 \times 10^{-3}$ ). This correlation becomes stronger only within the other *Enterococcus* species (Pearson's  $r=-0.34$ ,  $P=4.64 \times 10^{-3}$ ), but within *E. faecium* or *E. faecalis*, there is no significant correlation. On the other hand, the *Enterococcus* species are most resistant to quinupristin/dalfopristin (323 samples). This fraction is significantly more than the resistance to any other antibiotic (Fisher's exact test, corrected for multiple testing by using false discovery rate (FDR) (Tables 2 and 3) (29). After that, and by a large distance, the least effective antibiotics are fosfomycin/trometamol and gentamicin with 117 and 90 resistant samples, respectively. They are both significantly less effective than a teicoplanin and vancomycin (Table 2). There was no significant difference in the effectiveness of fosfomycin/trometamol and gentamicin. The most effective antibiotics were teicoplanin and vancomycin, with only 23 and 27 samples were resistant to them, respectively (Table 3).



**Fig. 2.** *Enterococcus* species and their resistance to five different antibiotics. A suffix of "sen" means sensitive to that antibiotic, "med" mean intermediate resistance, and "res" means resistant.

GM: gentamicin, VAN: vancomycin, FOT: fosfomycin trometamol, TEC: teicoplanin, SYN: quinupristin/dalfopristin.

**Table 2.** Correlation between resistance to selected antibiotics in isolated samples. There are significant differences between the numbers of resistant samples to one antibiotic versus the other. The rows are Fisher’s exact test’s odds ratio and its p-value, corrected for multiple testing by using FDR. The columns are comparisons between pairs of antibiotics.

|            | Antibiotics |          |          |          |          |          |           |          |          |           |
|------------|-------------|----------|----------|----------|----------|----------|-----------|----------|----------|-----------|
|            | GM-VAN      | GM-FOT   | GM-TEC   | GM-SYN   | VAN-FOT  | VAN-TEC  | VAN-SYN   | FOT-TEC  | FOT-SYN  | TEC-SYN   |
| odds ratio | 0.24933     | 1.42403  | 0.210139 | 14.4488  | 5.71143  | 0.842814 | 57.9505   | 0.147566 | 10.1464  | 68.7583   |
| p-value    | 2.88E-10    | 0.039638 | 8.26E-12 | 7.21E-64 | 5.27E-17 | 0.661648 | 1.19E-110 | 5.92E-19 | 4.31E-50 | 1.43E-114 |

GM: gentamicin, VAN: vancomycin, FOT: fosfomycin trometamol, TEC: teicoplanin, SYN: quinupristin/dalfopristin.

**Table 3.** The number of resistant samples to each antibiotic

| Antibiotic | Number of resistant samples |
|------------|-----------------------------|
| GM         | 90                          |
| VAN        | 27                          |
| FOT        | 117                         |
| TEC        | 23                          |
| SYN        | 323                         |

There was no difference between resistance to different antibiotics in *E. faecium* and *E. faecalis* (Fisher’s exact test, [Table 4](#)). According to the results, a large fraction of samples was resistant to multiple antibiotics. A minimum of 42.4% (*E. faecalis*) and a maximum of 58.1% (*E. faecium*) of samples were resistant to more than one antibiotic ([Table 5](#)). Most multi-resistant species were resistant to only two antibiotics, but between 1-2% of the samples were resistant to four antibiotics at the same time ([Table 5](#)). There was, however, no difference between the fractions of samples that were multi-resistant in different species. The number of samples that were co-resistant to

each pair of the antibiotics is shown in [Table 6](#). Co-resistance occurs between all pairs of antibiotics. The most common co-resistance occurred in case of fosfomycin/trometamol and quinupristin/dalfopristin (100 samples), and between gentamicin and quinupristin/dalfopristin (76 samples). The least common co-resistance was between gentamicin and vancomycin (6 samples). According to the findings, age and sex had no effect on resistance to any antibiotic. Using generalized linear models with logistic regression, we found no effect of age, sex or their combination on resistance to antibiotics.

**Table 4.** The number of resistant samples (*E. faecalis* and *E. faecium*) to different antibiotics. The last column shows Fisher's exact test p-values (corrected for multiple testing using FDR) for any difference between the numbers of resistant samples of the two species.

| Antibiotics | <i>E. faecalis</i> | <i>E. faecium</i> | P-value |
|-------------|--------------------|-------------------|---------|
| GM          | 61                 | 15                | 0.27    |
| VAN         | 18                 | 5                 | 0.42    |
| FOT         | 80                 | 14                | 0.68    |
| TEC         | 13                 | 4                 | 0.42    |
| SYN         | 234                | 34                | 0.68    |

**Table 5.** The fraction of samples that are simultaneously resistant to two or more antibiotics. The first column shows the number of antibiotics to which there is simultaneous resistance, and other columns show the fraction of all samples or fraction of samples within different species which are resistant to multiple antibiotics simultaneously. The last row is the sum of all rows above it.

| Simultaneous resistance (Number of antibiotics ) | All species  | <i>E. faecalis</i> | <i>E. faecium</i> | Other species |
|--|--------------|--------------------|-------------------|---------------|
| 2  | 0.343        | 0.330              | 0.419             | 0.348         |
| 3  | 0.090        | 0.080              | 0.140             | 0.101         |
| 4  | 0.015        | 0.014              | 0.023             | 0.014         |
| 5  | 0            | 0                  | 0                 | 0             |
| <b>sum</b>                                       | <b>0.448</b> | <b>0.424</b>       | <b>0.581</b>      | <b>0.464</b>  |

**Table 6.** The number of samples with co-resistance to different antibiotics by the antibiotics.

| Samples            | GM-VAN | GM-FOT | GM-TEC | GM-SYN | VAN-FOT | VAN-TEC | VAN-SYN | FOT-TEC | FOT-SYN | TEC-SYN |
|--------------------|--------|--------|--------|--------|---------|---------|---------|---------|---------|---------|
| <i>All species</i> | 6      | 25     | 7      | 76     | 11      | 10      | 23      | 8       | 100     | 15      |
| <i>E. faecalis</i> | 2      | 16     | 3      | 53     | 8       | 6       | 17      | 5       | 69      | 9       |
| <i>E. faecium</i>  | 2      | 3      | 2      | 12     | 1       | 3       | 3       | 1       | 13      | 2       |
| Other species      | 2      | 6      | 2      | 11     | 2       | 1       | 3       | 2       | 18      | 4       |

## Discussion

Over the past two decades, due to excessive consumption of antibiotics, resistance to common antibiotics has been increased (30-32). Accordingly, infections with methicillin-resistant *S. aureus* (MRSA) and vancomycin-resistant *Enterococcus* species (VRE) poses significant treatment challenges, which leads to an increase in treatment failure, relapse, and higher rates of mortality, as according to the reports mortality from enterococcal bacteremia is estimated at 15–35% (33). Vancomycin resistance in *Enterococcus* species has been increased in hospitalized patients and affected the treatment of *Enterococcus* infections (34-38). A report by the National Healthcare Safety Network in the United States shows that approximately 40% of majority of device-associated infections, such as urinary drainage catheters and ventilators, are associated with vancomycin- and ampicillin-resistant *E. faecium* with a prevalence of 80% and 90.4%, respectively. While, infections in these units which caused by *E. faecalis* remained largely susceptible

to ampicillin and vancomycin (96.2% and 93.1%, respectively) for reasons that are not entirely known (16, 39). However, molecular analyses have shown that *E. faecium* is intrinsically more resistant to antibiotics than *E. faecalis*, so that more than a half of the pathogenic isolates of this bacterium show resistance to vancomycin, ampicillin, and high-levels of aminoglycosides (40,41). According to clinical studies, many hospital-associated strains that are resistant to vancomycin also show resistance to penicillin, as well as high-level resistance to aminoglycosides. Therefore, the specific and accurate identification and determination of *Enterococcus* species and their antibiotic resistance pattern is important to provide an effective treatment protocol and the choice of right drug to treat infection and to avoid transfer of vancomycin-resistant plasmid from *Enterococcus* to main pathogen bacteria and other *Enterococcus* strains (42,43). Combination antibiotic therapy can be a significant strategy for treating infections caused by *Enterococcus*

species. Data showing that this strategy can lead to improved rates of cure and lower rates of relapse when compared to monotherapy (5,18). Currently, combination therapy of a cell wall-active agent such as vancomycin, teicoplanin, and fosfomycin trometamol plus an aminoglycoside like gentamycin and quinupristin/dalfopristin is as a standard protocol for treatment of enterococcal infections (44). It has been shown that the use of aminoglycosides with penicillin as cell wall-active antibiotic produced synergistic activity and improve the cure rates for enterococcal infective endocarditis from 40 to 88% (45). However, although the recommended regimens currently include the use of two or more antibiotics, inappropriate and long-term use of these antibiotics can also lead to drug resistance (30,44). Therefore, the correct selection of antibiotics and understanding the relationship between antibiotic resistances can reduce this risk. Accordingly, in the current study, 72% of samples were infected with *E. faecalis*, 10.75% with *E. faecium*, and 17.25% with other *Enterococcus* species. Our results showed that among *E. faecalis* and *E. faecium* isolates, resistance to cell wall-active antibiotics (vancomycin, teicoplanin, and fosfomycin trometamol) were 33.5% and 53.5%, respectively, which are consistent with its global prevalence (8, 40, 46). However, among *E. faecalis* and *E. faecium* isolates the highest resistance was to fosfomycin trometamol antibiotic (27% and 32%, respectively) while for the other two antibiotics it was almost the same (5.5% and 10%, respectively). In this study, a high rate of resistance to fosfomycin was observed, while this antibiotic is as an alternative antibiotic against multidrug resistant organisms, including vancomycin-resistant enterococcus (VRE) and extended-spectrum  $\beta$ -lactamase (ESBL) (47) which could be due to its excessive and inappropriate use. In addition, according to many reported studies (48-50), *E. faecalis* and *E. faecium* isolates exhibit high resistance to aminoglycosides including gentamycin and quinupristin/dalfopristin. Our findings showed that 21% of *E. faecalis* and 35% of *E. faecium* isolates are resistant to gentamycin while a high number of isolates were resistant to quinupristin/dalfopristin (81% and 79%, respectively).

Similar to this study, there have been extensive studies in Iran and other countries. For instance, in a study by Shahraki *et al.*, (2017) 182 samples were collected from southeast of Iran. Among samples, 63 and 22 cases were caused by *E. faecalis* and *E. faecium* strains, respectively. According to their reports, only 6 *E. faecalis* and 12 *E. faecium* isolates were resistant to vancomycin (51), which is different from our results because more than 50% of *E. faecium* show resistance to vancomycin while in current study the resistance rate is about 10%. In addition, Arbabi *et*

*al.*, (2016) determined 149 *Enterococcus* species and their resistance pattern isolated from clinical samples of some hospitals in Tehran, Iran. Among isolates, 60% and 26% were of *E. faecalis* and *E. faecium*, respectively. About 33 strains of VRE, more than a half of the isolates were *E. faecium*, and *E. faecalis* was in the second place (52). In contrast to the findings in these studies, a lower prevalence of *E. faecalis* has been reported by Labib Azza *et al.*, (2013) in Egypt (53). They identified *Enterococcus* species by phenotypic and molecular methods and found significant differences between the frequency of *E. faecalis* (32%) and *E. faecium* (48%) infections. In addition, 60% isolates were identified as VRE. Also, a study in Iraq by Al-Hadithi and Rasheed (2018) (54) showed that among 57 isolates of *E. faecalis* (N=42) and *E. faecium* (N=15) which were isolated from infected wounds higher percentage of vancomycin resistance is associated with *E. faecium* (53.3%) as compared to *E. faecalis* (47.6%), which is similar to other studies performed in Iran. It is noteworthy that compared to these studies, our results showed that more than 90% of the isolated samples were susceptible to vancomycin.

Generally, in the present study, we found resistance to the first-line treatment, i.e., aminoglycosides. We also found resistance to substituting antibiotics such as vancomycin and teicoplanin, although at lower levels especially for vancomycin. However, according to the studies the high transformability of glycopeptides in *Enterococci* help develop resistance to different antibiotics (55). On the other hand, the statistical analysis of resistance in the *Enterococcus* species showed a prevalence of multi-resistant species. More than 40% of samples from different species are resistant to more than two antibiotics, and a small fraction of 1%-2% have gained resistance to four antibiotics (Table 5). This can be an alarming beginning of increased resistance to common antibiotics in *Enterococci*, especially that there are no two antibiotics in our list to which co-resistance has not evolved. We found a strong positive correlation between resistance to vancomycin and teicoplanin with similar rate of resistance. This suggests that if one of these two antibiotics was not effective in the treatment of an *Enterococci* infection, the other one will likely not be effective and should not be prescribed, because, the mechanism of action of vancomycin and teicoplanin, both from glycopeptides family, is the same (55). These inhibit growth of bacteria by interfering peptidoglycan biosynthesis. Additionally, we found a negative correlation between sensitivity to vancomycin and fosfomycin trometamol. Fosfomycin trometamol, a broad-spectrum penicillin, despite having a similar mechanism of action to teicoplanin, is effective on strains with resistance to vancomycin and vice

versa. The effectiveness of different of antibiotics with respect to one another is shown in Tables 2 and 3. Briefly, teicoplanin and vancomycin are the most effective antibiotics, followed by fosfomycin trometamol and gentamicin. quinupristin/dalfopristin, being ineffective on 80.75% (323) of the samples, seems to be a poor choice to treatment of *Enterococci* infections.

### Conclusion

In sum, we showed a detailed resistance pattern of clinically isolated *Enterococci* species to five common antibiotics. Our results are not merely descriptive; using statistical analysis, we distinguish between resistance patterns that may have occurred due to chance alone and patterns that are unlikely to have occurred by chance. Our findings showed positive and negative correlations between the resistance to common antibiotics in these bacteria. Accordingly, the results confirmed the association between simultaneous resistance to vancomycin and teicoplanin. These results can guide antibiotic prescriptions against *Enterococci* infections.

### Acknowledgements

The authors acknowledge the valuable contribution of the staff of Islamic Azad University of Varamin-Pishva Branch, Tehran, Iran.

### Conflict of Interest

The authors declared that there is no conflict of interest regarding the publication of this article.

### References

- Moghimbeygi A, Moghimbeygi M, Dousti M, Kiani F, Sayehmiri F, Sadeghifard N, et al. et al. Prevalence of vancomycin resistance among isolates of enterococci in Iran: a systematic review and meta-analysis. *Adolescent health, medicine and therapeutics*. 2018;9:177. [DOI:10.2147/AHMT.S180489] [PMID] [PMCID]
- Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. *PloS one*. 2017;12(12):e0189621. [DOI:10.1371/journal.pone.0189621] [PMID] [PMCID]
- Arshadi M, Mahmoudi M, Motahar MS, Soltani S, Pourmand MR. Virulence Determinants and Antimicrobial Resistance Patterns of Vancomycin-resistant *Enterococcus faecium* Isolated from Different Sources in Southwest Iran. *Iranian journal of public health*. 2018;47(2):264.
- Azizi R, Alemrajabi M, Naderan M, Shoar S. Efficacy of modified Limberg flap in surgical treatment of infected pilonidal abscess: a case-control study. *European Surgery*. 2014;46(4):144-7. [DOI:10.1007/s10353-014-0273-9]
- Bartash R, Nori P. Beta-lactam combination therapy for the treatment of *Staphylococcus aureus* and *Enterococcus* species bacteremia: A summary and appraisal of the evidence. *International Journal of Infectious Diseases*. 2017;63:7-12. [DOI:10.1016/j.ijid.2017.07.019] [PMID]
- Amani J, A Barjini K, M Moghaddam M, Asadi A. In vitro synergistic effect of the CM11 antimicrobial peptide in combination with common antibiotics against clinical isolates of six species of multidrug-resistant pathogenic bacteria. *Protein and peptide letters*. 2015;22(10):940-51. [DOI:10.2174/0929866522666150728115439] [PMID]
- Choopani A, Golmohammadi R, Rafati H, Imani Fooladi A. Prevalence of *Staphylococcus aureus* strains isolated from wound infection and drug sensitivity pattern, Tehran-Iran (2006-07). *J Gorgan Univ Med Sci*. 2012;14(3):135-40.
- Tan SC, Chong CW, Teh CSJ, Ooi PT, Thong KL. Occurrence of virulent multidrug-resistant *Enterococcus faecalis* and *Enterococcus faecium* in the pigs, farmers and farm environments in Malaysia. *PeerJ*. 2018;6:e5353. [DOI:10.7717/peerj.5353] [PMID] [PMCID]
- Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial Infections in Combined Medical-Surgical Intensive Care Units in the United States. *Infection Control & Hospital Epidemiology*. 2000;21(8):510-5. [DOI:10.1086/501795] [PMID]
- Custovic A, Smajlovic J, Hadzic S, Ahmetagic S, Tihic N, Hadzagic H. Epidemiological Surveillance of Bacterial Nosocomial Infections in the Surgical Intensive Care Unit. *Materia Socio-Medica*. 2014;26(1):7-11. [DOI:10.5455/msm.2014.26.7-11] [PMID] [PMCID]
- Van den Berghe E, De Winter T, De Vuyst L. Enterocin A production by *Enterococcus faecium* FAIR-E 406 is characterised by a temperature- and pH-dependent switch-off mechanism when growth is limited due to nutrient depletion. *International Journal of Food Microbiology*. 2006;107(2):159-70. [DOI:10.1016/j.ijfoodmicro.2005.08.027] [PMID]
- Schröder U-C, Beleites C, Assmann C, Glaser U, Hübner U, Pfister W, et al. et al. Detection of vancomycin resistances in

- enterococci within 3 ½ hours. Scientific reports. 2015;5:8217. [DOI:10.1038/srep08217] [PMID] [PMCID]
13. Moradi M, Ghosian MH, Yaghout poor E. Assessment of Hyoscyamus niger seeds alcoholic extract effects on acute and chronic pain in male NMRI rats. Journal of Basic and Clinical Pathophysiology. 2012;1(1):29-36.
  14. Kristich CJ, Rice LB, Arias CA. Enterococcal infection-treatment and antibiotic resistance. 2014.
  15. Chakraborty A, Pal N, Sarkar S, Gupta M. Antibiotic resistance pattern of *Enterococci* isolates from nosocomial infections in a tertiary care hospital in Eastern India. Journal of Natural Science, Biology and Medicine. 2015;6(2):394-7. [DOI:10.4103/0976-9668.160018] [PMID] [PMCID]
  16. Agudelo Higueta NI, Huycke MM. Enterococcal Disease, Epidemiology, and Implications for Treatment. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: From Commensals to Leading Causes of Drug Resistant Infection. Boston: Massachusetts Eye and Ear Infirmary; 2014.
  17. Rivera AM, Boucher HW. Current Concepts in Antimicrobial Therapy Against Select Gram-Positive Organisms: Methicillin-Resistant *Staphylococcus aureus*, Penicillin-Resistant *Pneumococci*, and Vancomycin-Resistant *Enterococci*. Mayo Clinic Proceedings. 2011;86(12):1230-43. [DOI:10.4065/mcp.2011.0514] [PMID] [PMCID]
  18. Beganovic M, Luther MK, Rice LB, Arias CA, Rybak MJ, LaPlante KL. A Review of Combination Antimicrobial Therapy for *Enterococcus Faecalis* Bloodstream Infections and Infective Endocarditis. Clinical Infectious Diseases. 2018. [DOI:10.1093/cid/ciy064] [PMID] [PMCID]
  19. Azizi R, Alvandipour M, Bijari A, Shoar S, Alemrajabi M. Clinical outcome after stapled transanal rectal resection for obstructed defecation syndrome: the first Iranian experience. European Surgery. 2013;45(1):21-5. [DOI:10.1007/s10353-013-0189-9]
  20. Devriese L, Van de Kerckhove A, Kilpper-Bälz R, Schleifer K. Characterization and identification of *Enterococcus* species isolated from the intestines of animals. International Journal of Systematic and Evolutionary Microbiology. 1987;37(3):257-9. [DOI:10.1099/00207713-37-3-257]
  21. Honarm H, Falah Ghavidel M, Nikokar I, Rahbar Taromsari M. Evaluation of a PCR Assay to Detect *Enterococcus faecalis* in Blood and Determine Glycopeptides Resistance Genes: Van A and Van B. Iranian Journal of Medical Sciences. 2012;37(3):194-9.
  22. Tsai J-C, Hsueh P-R, Lin H-M, Chang H-J, Ho S-W, Teng L-J. Identification of Clinically Relevant *Enterococcus* Species by Direct Sequencing of *groES* and *Spacer* Region. Journal of Clinical Microbiology. 2005;43(1):235-41. [DOI:10.1128/JCM.43.1.235-241.2005] [PMID] [PMCID]
  23. Jackson CR, Fedorka-Cray PJ, Barrett JB. Use of a Genus- and Species-Specific Multiplex PCR for Identification of *Enterococci*. Journal of Clinical Microbiology. 2004;42(8):3558-65. [DOI:10.1128/JCM.42.8.3558-3565.2004] [PMID] [PMCID]
  24. (CLSI) CaLSI. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing Wayne, PA: Clin Labora Stand Institu; 2015 [
  25. Mirnejad R, Sajjadi N, Masoumi Zavaryani S, Piranfar V, Hajhosseini M, Roshanfekr M. Identification of aminoglycoside resistance genes by Triplex PCR in *Enterococcus* spp. isolated from ICUs. Infez Med. 2016;24(3):222-9.
  26. Moghaddam MM, Barjini KA, Ramandi MF, Amani J. Investigation of the antibacterial activity of a short cationic peptide against multidrug-resistant *Klebsiella pneumoniae* and *Salmonella typhimurium* strains and its cytotoxicity on eukaryotic cells. World Journal of Microbiology and Biotechnology. 2014;30(5):1533-40. [DOI:10.1007/s11274-013-1575-y] [PMID]
  27. Naserpour Farivar T, Najafipour R, Johari P, Aslanimehr M, Peymani A, Jahani Hashemi H, et al. et al. Development and evaluation of a Quadruplex Taq Man real-time PCR assay for simultaneous detection of clinical isolates of *Enterococcus faecalis*, *Enterococcus faecium* and their *vanA* and *vanB* genotypes. Iranian Journal of Microbiology. 2014;6(5):335-40.
  28. Traub WH, Geipel U, Leonhard B. Antibiotic Susceptibility Testing (Agar Disk Diffusion and Agar Dilution) of Clinical Isolates of *Enterococcus faecalis* and *E. faecium*: Comparison of Mueller-Hinton, Iso-Sensitest, and Wilkins-Chalgren Agar Media. Chemotherapy. 1998;44(4):217-29. [DOI:10.1159/000007118] [PMID]
  29. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing.

- Journal of the Royal Statistical Society Series B (Methodological). 1995;57(1):289-300. [DOI:10.1111/j.2517-6161.1995.tb02031.x]
30. Azad ZM, Moravej H, Fasihi-Ramandi M, Masjedian F, Nazari R, Mirnejad R, et al. et al. In vitro synergistic effects of a short cationic peptide and clinically used antibiotics against drug-resistant isolates of *Brucella melitensis*. *Journal of medical microbiology*. 2017;66(7):919-26. [DOI:10.1099/jmm.0.000524] [PMID]
  31. Moravej H, Moravej Z, Yazdanparast M, Heiat M, Mirhosseini A, Moosazadeh Moghaddam M, et al. et al. Antimicrobial peptides: features, action, and their resistance mechanisms in bacteria. *Microbial Drug Resistance*. 2018;24(6):747-67. [DOI:10.1089/mdr.2017.0392] [PMID]
  32. Haj Ebrahim Tehrani F, Moradi M, Ghorbani N. Bacterial Etiology and Antibiotic Resistance Patterns in Neonatal Sepsis in Tehran during 2006-2014. *Iranian Journal of Pathology*. 2017;12(4):356-61.
  33. Furuno JP, Perencevich EN, Johnson JA, Wright M-O, McGregor JC, Morris Jr JG, et al. et al. Methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci co-colonization. *Emerging infectious diseases*. 2005;11(10):1539. [DOI:10.3201/eid1110.050508] [PMID] [PMCID]
  34. Heintz BH, Halilovic J, Christensen CL. Vancomycin-Resistant Enterococcal Urinary Tract Infections. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 2010;30(11):1136-49. [DOI:10.1592/phco.30.11.1136] [PMID]
  35. Shokoohzadeh L, Ekrami A, Labibzadeh M, Ali L, Alavi SM. Antimicrobial resistance patterns and virulence factors of enterococci isolates in hospitalized burn patients. *BMC research notes*. 2018;11(1):1. [DOI:10.1186/s13104-017-3088-5] [PMID] [PMCID]
  36. Tripathi A, Shukla S, Singh A, Prasad K. Prevalence, outcome and risk factor associated with vancomycin-resistant *Enterococcus faecalis* and *Enterococcus faecium* at a Tertiary Care Hospital in Northern India. *Indian journal of medical microbiology*. 2016;34(1):38. [DOI:10.4103/0255-0857.174099] [PMID]
  37. Hosseini MJ, Sadripour R. Antibiotic Resistance pattern of bacteria isolated from nosocomial infection in internal surgery and neurosurgery intensive care unit (NICU) at a tertiary care hospital in Tehran, Iran. *Biosciences Biotechnology Research Asia*. 2017;14(3):1095-102. [DOI:10.13005/bbra/2547]
  38. Heiat M, Aghamollaei H, Moghaddam MM, Kooshki H. Using CM11 peptide as a cell permeable agent for the improvement of conventional plasmid transformation methods in *Escherichia coli* and *Bacillus subtilis*. *Minerva Biotechnol*. 2014;26:149-57.
  39. Bourdon N, Fines-Guyon M, Thiolet J-M, Maugat S, Coignard B, Leclercq R, et al. et al. Changing trends in vancomycin-resistant enterococci in French hospitals, 2001-08. *Journal of antimicrobial chemotherapy*. 2011;66(4):713-21. [DOI:10.1093/jac/dkq524] [PMID]
  40. Akpaka PE, Kissoon S, Jayaratne P, Wilson C, Golding GR, Nicholson AM, et al. et al. Genetic characteristics and molecular epidemiology of vancomycin-resistant Enterococci isolates from Caribbean countries. *PloS one*. 2017;12(10):e0185920. [DOI:10.1371/journal.pone.0185920] [PMID] [PMCID]
  41. Hassan MM, Belal E-SB. Antibiotic resistance and virulence genes in enterococcus strains isolated from different hospitals in Saudi Arabia. *Biotechnology & Biotechnological Equipment*. 2016;30(4):726-32. [DOI:10.1080/13102818.2016.1184992]
  42. Murray BE. Vancomycin-Resistant Enterococcal Infections. *New England Journal of Medicine*. 2000;342(10):710-21. [DOI:10.1056/NEJM200003093421007] [PMID]
  43. Lavová M, Bezekova J, Čanigová M, Krocko M, Domig K. Species identification of enterococci by biochemical test and molecular-genetic methods 2014. 124-9 p. [DOI:10.5219/364]
  44. Yim J, Smith JR, Rybak MJ. Role of Combination Antimicrobial Therapy for Vancomycin-Resistant *Enterococcus faecium* Infections: Review of the Current Evidence. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 2017;37(5):579-92. [DOI:10.1002/phar.1922] [PMID]
  45. Miller WR, Munita JM, Arias CA. Mechanisms of antibiotic resistance in enterococci. *Expert review of anti-infective therapy*. 2014;12(10):1221-36. [DOI:10.1586/14787210.2014.956092] [PMID] [PMCID]
  46. Yuen GJ, Ausubel FM. *Enterococcus Infection Biology: Lessons from Invertebrate Host Models*. *Journal of microbiology (Seoul, Korea)*. 2014;52(3):200-10.

- [DOI:10.1007/s12275-014-4011-6] [PMID] [PMCID]
47. Nagel JL, Washer L, Kunapuli A, Heidmann J, Pisani J, Gandhi T. Clinical efficacy of fosfomycin for the treatment of complicated lower tract and uncomplicated urinary tract infections. *International Archives of Medicine*. 2015;8. [DOI:10.3823/1750]
  48. Adhikari L. High-level aminoglycoside resistance and reduced susceptibility to vancomycin in nosocomial enterococci. *Journal of global infectious diseases*. 2010;2(3):231. [DOI:10.4103/0974-777X.68534] [PMID] [PMCID]
  49. Mittal S, Singla P, Deep A, Bala K, Sikka R, Garg M, et al. Vancomycin and high level aminoglycoside resistance in *Enterococcus* spp. in a tertiary health care centre: a therapeutic concern. *Journal of pathogens*. 2016;2016. [DOI:10.1155/2016/8262561] [PMID] [PMCID]
  50. Ngbede EO, Raji MA, Kwanashie CN, Kwaga JK, Adikwu AA, Maurice NA, et al. Characterization of high level ampicillin-and aminoglycoside-resistant enterococci isolated from non-hospital sources. *Journal of medical microbiology*. 2017;66(7):1027-32. [DOI:10.1099/jmm.0.000518] [PMID]
  51. Shahraki S, Mousavi MRN. Determination of Virulence Factors in Clinical Multidrug Resistance Enterococci Isolates at Southeast of Iran. *Jundishapur Journal of Microbiology*. 2017;10(5). [DOI:10.5812/jjm.45514]
  52. Arbabi L, Boustanshenas M, Rahbar M, Owlia P, Adabi M, Koohi SR, et al. Antibiotic susceptibility pattern and virulence genes in *Enterococcus* spp. isolated from clinical samples of Milad hospital of Tehran, Iran. *Archives of Clinical Infectious Diseases*. 2016;11(3). [DOI:10.5812/archcid.36260]
  53. Azza L, Ahmed M, Nahed AR, Wafaa Z, Eman E. Molecular and phenotypic characterization of hospital-associated and community-associated isolates of *Enterococcus* spp. *Menoufia Medical Journal*. 2013;26(2):108-13. [DOI:10.4103/1110-2098.126138]
  54. Al-Hadithi HT, Rasheed K. Infected Wounds. Incidence of High-level Resistance to Vancomycin and Aminoglycosides.
  55. Binda E, Marinelli F, Marcone LG. Old and New Glycopeptide Antibiotics: Action and Resistance. *Antibiotics*. 2014;3(4). [DOI:10.3390/antibiotics3040572] [PMID] [PMCID]
  56. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. *Journal of Clinical Microbiology*. 1995;33(1):24-7. [DOI:10.1128/JCM.33.1.24-27.1995] [PMID] [PMCID]

#### How to Cite This Article

Masoumi Zavaryani, S., Mirnejad, R., Piranfar, V., Moosazadeh Moghaddam, M., Sajjadi, N., Saeedi, S. Assessment of Susceptibility to Five Common Antibiotics and Their Resistance Pattern in Clinical Enterococcus Isolates. *Iranian Journal of Pathology*, 2020; 15(2): 96-105. doi: 10.30699/ijp.2020.114009.2236